STOCK TITAN

TriSalus (TLSI) CCO logs small tax-related share disposals, retains over 110K shares

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

TriSalus Life Sciences Chief Commercial Officer Richard Marshak reported routine share disposals tied to tax withholding, not discretionary selling. Over three days, he disposed of a total of 3,457 shares of common stock at prices between $4.09 and $4.13 per share. A footnote explains these shares were sold solely to satisfy tax obligations from vesting restricted stock units previously granted to him. After these transactions, Marshak continues to hold 110,397 shares of TriSalus common stock directly, indicating the disposals are small relative to his remaining stake.

Positive

  • None.

Negative

  • None.
Insider Marshak Richard
Role Chief Commercial Officer
Sold 3,457 shs ($14K)
Type Security Shares Price Value
Sale Common Stock 419 $4.12 $2K
Sale Common Stock 1,589 $4.09 $6K
Sale Common Stock 1,449 $4.13 $6K
Holdings After Transaction: Common Stock — 110,397 shares (Direct)
Footnotes (1)
  1. [object Object]
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Marshak Richard

(Last)(First)(Middle)
6272 W. 91ST AVENUE

(Street)
WESTMINSTER COLORADO 80031

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/11/2026S1,449(1)D$4.13112,405D
Common Stock03/12/2026S1,589(1)D$4.09110,816D
Common Stock03/16/2026S419(1)D$4.12110,397D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.
Remarks:
/s/ Mary Szela, Attorney-in-Fact03/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TriSalus Life Sciences (TLSI) insider Richard Marshak report on this Form 4?

Richard Marshak reported disposing of 3,457 TriSalus common shares. The transactions occurred over three days in March at prices slightly above $4.00 per share and were linked to tax withholding on previously granted restricted stock units.

Were Richard Marshak’s TLSI share disposals discretionary open-market sales?

No, the filing states the shares were sold to satisfy tax withholding obligations. A footnote clarifies the transactions do not represent discretionary sales, but rather automatic disposals related to vesting of restricted stock units granted as compensation.

How many TriSalus (TLSI) shares did Richard Marshak dispose of and at what prices?

He disposed of 3,457 common shares in total. The reported per-share prices were $4.12, $4.09, and $4.13 on different days, reflecting small, tax-related transactions rather than large portfolio changes.

How many TriSalus (TLSI) shares does Richard Marshak hold after these transactions?

Following the reported tax-related disposals, Marshak directly holds 110,397 TriSalus common shares. This indicates the transactions affected only a small portion of his position, leaving his overall ownership in the company largely unchanged.

What is the purpose of the share sales disclosed in this TriSalus (TLSI) Form 4?

The purpose was to cover tax withholding obligations arising from vesting restricted stock units. The filing’s footnote emphasizes these sales were not discretionary investment decisions, but mechanical transactions tied to compensation-related equity vesting.
TriSalus Life Sciences Inc.

NASDAQ:TLSI

View TLSI Stock Overview

TLSI Rankings

TLSI Latest News

TLSI Latest SEC Filings

TLSI Stock Data

236.03M
39.06M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
WESTMINSTER